Automate Your Wheel Strategy on BIIB
With Tiblio's Option Bot, you can configure your own wheel strategy including BIIB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
Read More
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
Published: March 31, 2026 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
Read More
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
Published: March 31, 2026 by: Proactive Investors
Sentiment: Positive
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved.
Read More
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Published: March 31, 2026 by: Zacks Investment Research
Sentiment: Positive
BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.
Read More
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy
Published: March 30, 2026 by: Benzinga
Sentiment: Positive
• Biogen stock is moving in positive territory. Why is BIIB stock advancing?
Read More
Biogen high-dose Spinraza approval seen supporting long-term growth
Published: March 30, 2026 by: Proactive Investors
Sentiment: Positive
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal muscular atrophy (SMA), a move analysts at Jefferies say could help sustain the company's long-standing position in the rare disease market. According to the analysts, the decision was largely anticipated by investors despite earlier regulatory delays tied to manufacturing issues described as “benign.
Read More
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Published: March 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
Read More
Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript
Published: March 18, 2026 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript
Read More
Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Published: February 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Read More
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Published: February 06, 2026 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Read More
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
Read More
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
These Are The Worst 25 Stocks to Own in February
Published: February 03, 2026 by: Schaeffers Research
Sentiment: Negative
It's been an interesting start to the year, with plenty of geopolitical developments for investors to unpack.
Read More
New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.
Read More
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Negative
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
BIIB secures FDA's Breakthrough Therapy status for litifilimab in cutaneous lupus, backed by phase II results, while advancing phase III and broader lupus studies.
Read More
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Published: January 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases.2 The SPINRAZA European Union marketing authorization has been updated to include the high dose regimen. The new high dose regimen comprises a more rapid loading phase, two 50 mg loading doses …
Read More
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
Published: December 30, 2025 by: Seeking Alpha
Sentiment: Positive
Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia, as a driver of Biogen's EBIT growth. Its sales totaled $132.9 million in Q3, up 29.9% year-over-year.
Read More
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension (OLE) study evaluating QALSODY® (tofersen) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) with over 3.5 years of follow-up. These results show that early initiation of QALSODY was associated with numerically slower decline in measures of clinical function, breathing and strength, as well as reduction in the risk of death or permanent ventilation. Sustained reductions in …
Read More
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Published: December 05, 2025 by: Business Wire
Sentiment: Neutral
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES).
Read More
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Published: December 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life—
Read More
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Read More
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Biogen shares could climb on Leqembi uptake – Jefferies
Published: November 28, 2025 by: Proactive Investors
Sentiment: Positive
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) could see its stock move higher over the next two years as progress on its Alzheimer's drug Leqembi and a series of late-stage pipeline readouts draw more investor attention, according to Jefferies. The broker, which rates the stock Buy with a price target of $210, said Leqembi's trajectory in early Alzheimer's disease “could accelerate” if a subcutaneous induction version wins approval in mid-2026, enabling full at-home use.
Read More
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
Read More
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Read More
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
About Biogen Inc. (BIIB)
- IPO Date 1991-09-17
- Website https://www.biogen.com
- Industry Drug Manufacturers - General
- CEO Christopher A. Viehbacher
- Employees 7605